Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
2.78% $0.720
America/New_York / 17 apr 2024 @ 15:31
FUNDAMENTALS | |
---|---|
MarketCap: | 29.61 mill |
EPS: | -1.240 |
P/E: | -0.580 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 41.15 mill |
Avg Daily Volume: | 1.335 mill |
RATING 2024-04-17 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.580 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -0.580 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.301 - 1.139 ( +/- 58.19%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Novo Holdings A/s | Sell | 465 021 | COMMON STOCK |
2024-03-18 | Novo Holdings A/s | Sell | 842 020 | COMMON STOCK |
2024-03-19 | Novo Holdings A/s | Sell | 593 000 | COMMON STOCK |
2024-03-20 | Novo Holdings A/s | Sell | 359 979 | COMMON STOCK |
2024-03-14 | Novo Holdings A/s | Sell | 1 912 316 | COMMON STOCK |
INSIDER POWER |
---|
3.35 |
Last 98 transactions |
Buy: 11 294 782 | Sell: 4 967 660 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.720 (2.78% ) |
Volume | 0.527 mill |
Avg. Vol. | 1.335 mill |
% of Avg. Vol | 39.49 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 12 - 11:21 | buy | $4.40 | N/A | Active |
---|
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.